CompletedPhase 2NCT03218917
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Insmed Incorporated
- Principal Investigator
- Carlos Fernandez, MDInsmed Incorporated
- Intervention
- Brensocatib 10 mg(drug)
- Enrollment
- 256 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2017 – 2019
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Medical Group, Peoria, Arizona, United States
- NewportNativeMD, Newport Beach, California, United States
- Palmtree Clinical Research, Palm Springs, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Stanford University Medical Center, Stanford, California, United States
- National Jewish Heath, Denver, Colorado, United States
- UConn Health Center, Farmington, Connecticut, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Clinical Research Specialists, LLC, Celebration, Florida, United States
- St. Francis Medical Institute, Clearwater, Florida, United States
- University of Florida, Gainesville, Florida, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States
- Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03218917 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.